News

News

  • New Publications by Dr. George Lau:

    1. “Five-year overall survival update from the HIMALAYA Study of tremelimumab plus durvalumab in unresectable HCC”. J Hepatol. 2025 Apr 11:S0168-8278(25)00226-0. doi: 10.1016/j.jhep.2025.03.033. PMID: 40222621

    2. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology. 2025 May 16, doi: 10.1097/HEP.0000000000001385 Epub ahead of print. PMID: 40384092.

    3. Apasl Viral Elimination Task Force. Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination. Hepatol Int. 2025 Apr;19(2):349-357. doi: 10.1007/s12072-024-10744-9. Epub 2025 Feb 3. PMID: 39900677; PMCID: PMC12003510.

    4. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025 Apr;19(2):261-301. doi: 10.1007/s12072-024-10774-3. Epub 2025 Feb 27. PMID: 40016576.

    5. Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure. Am J Gastroenterol. 2025 Apr 1;120(4):816-826. doi: 10.14309/ajg.0000000000002951. Epub 2024 Jul 17. PMID: 39016385.

  • Colorectal Cancer study is now starting recruitment! Click for more details

    Breast Cancer study is still under recruitment! Click for more details.

  • Manuscript acceptance: Title "Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma" has bee accepted for publication in Journal of Hepatology (IF=26.8)

  • HnH CTC becomes a strategic partner with AstraZeneca! Click for more details.

  • Nonalcoholic Steatohepatitis (NASH) study is now starting recruitment! COMPLETED

  • New Gastric Cancer study started recruitment!! COMPLETED

  • Non-Small-Cell Lung Cancer with KRAS G12C mutation (previously treated) - COMPLETED

    Gastrointestinal stroma tumors (previously treated with Imatinib) - COMPLETED

    KRAS G12C mutation colorectal cancer (previously treated) -COMPLETED

  • Phase III Study Advanced Colorectal Cancer with KRAS G12C Mutation (COMPLETED)

  • Phase III Study of Second Generation ALK Inhibitors for ALK positive NSCLC (Closed)

  • Phase III Study of Immunotherapy for non-EGFR or ALK genomic tumor aberrations NSCLC (CLOSED)

  • COVID-19 and Clinical Trials at H&H Clinical Trial Centre description

  • Phase III Study of Immunotherapy for Locoregional Hepatocellular Carcinoma (CLOSED)

  • Phase III Study of Immunotherapy & Chemotherapy Combination for Advanced Biliary Tract Cancer (CLOSED)

  • Phase III Study of Monoclonal Antibody Therapy for Idiopathic Pulmonary Fibrosis (CLOSED)

  • Phase III Study of Immunotherapy for Hepatocellular Carcinoma (CLOSED)

  • Phase III Study of Target Therapy for Advanced Hepatocellular Carcinoma (CLOSED)

  • Phase III Study for Unresectable Hepatocellular Carcinoma - RECRUITING! (CLOSED)